Co-Authors
This is a "connection" page, showing publications co-authored by SANJEEV VASUDEVAN and PAVEL SUMAZIN.
Connection Strength
1.213
-
A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma. J Hepatol. 2024 Apr; 80(4):610-621.
Score: 0.246
-
Navigating relapsed hepatoblastoma: Predictive factors and surgical treatment strategy. Cancer Med. 2023 12; 12(23):21270-21278.
Score: 0.243
-
HepT1-derived murine models of high-risk hepatoblastoma display vascular invasion, metastasis, and circulating tumor cells. Biol Open. 2022 09 15; 11(9).
Score: 0.224
-
Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults. J Hepatol. 2022 10; 77(4):1026-1037.
Score: 0.219
-
Author Correction: MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma. Sci Rep. 2021 Oct 01; 11(1):19916.
Score: 0.052
-
CHAF1A Blocks Neuronal Differentiation and Promotes Neuroblastoma Oncogenesis via Metabolic Reprogramming. Adv Sci (Weinh). 2021 10; 8(19):e2005047.
Score: 0.052
-
Restoration of the molecular clock is tumor suppressive in neuroblastoma. Nat Commun. 2021 06 28; 12(1):4006.
Score: 0.051
-
MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma. Sci Rep. 2021 02 03; 11(1):2967.
Score: 0.050
-
A Novel Cell Line Based Orthotopic Xenograft Mouse Model That Recapitulates Human Hepatoblastoma. Sci Rep. 2017 12 19; 7(1):17751.
Score: 0.040
-
Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer. J Hepatol. 2016 08; 65(2):325-33.
Score: 0.036